We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer has partnered with Beam Therapeutics to develop messenger RNA (mRNA)-based therapies for rare genetic diseases — a move to expand its portfolio of mRNA technology used to produce its landmark COVID-19 vaccine. Read More
France’s Sanofi and UK-based Exscientia have struck a deal potentially worth $5.2 billion to develop up to 15 new therapies for cancer and immunology indications using Exscientia’s artificial intelligence-based drug discovery platform. Read More
In a collaboration potentially valued at $1.9 billion, Amgen is teaming up with Cambridge, Mass.-based Generate Biomedicines to develop protein therapeutics for up to five clinical targets. Read More